# OnCo record hma (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/hma/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "hma" ;
  schema:name "Hypomethylating agents (azacitidine, decitabine)"@en ;
  schema:alternateName "HMA"@en, "HMAs"@en, "hypomethylating"@en, "hypomethylating agent"@en, "hypomethylating agents"@en, "oral azacitidine"@en, "oral decitabine-cedazuridine"@en, "venetoclax-azacitidine"@en, "venetoclax + azacitidine"@en, "ven-aza"@en, "Ven/Aza"@en, "HMA-venetoclax"@en, "venetoclax + HMA"@en, "HMA failure"@en ;
  schema:description "Low-intensity chemotherapy that strips chemical 'off' switches (methyl groups) from DNA so silenced genes can be read again. The mainstay for older patients with AML and high-risk MDS, especially combined with venetoclax."@en ;
  schema:url <https://onco.cc/terms/hma/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Azacitidine> ;
  schema:citation <https://en.wikipedia.org/wiki/Azacitidine> ;
  onco:related <https://onco.cc/cancers/mds/>, <https://onco.cc/terms/seven-plus-three/>, <https://onco.cc/terms/performance-status/> ;
  onco:cancers <https://onco.cc/cancers/aml/> ;
  onco:sections <https://onco.cc/fronts/epigenetics/>, <https://onco.cc/fronts/chemotherapy/> ;
  onco:technologies <https://onco.cc/technologies/epigenetic-drugs/> ;
  onco:drugs <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/drugs/venetoclax/> .